Synlogic stock.

SYNLOGIC INVESTOR CONTACT: Daniel Rosan Synlogic, Inc. 617-401-9152 [email protected] SYNLOGIC MEDIA CONTACT: Jenna Urban Berry & Company Public Relations 212-253-8881 [email protected]

Synlogic stock. Things To Know About Synlogic stock.

Synlogic, Inc. CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S ...CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU).Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI Science 37's Metasite ...Fourth Quarter 2022 Financial Results. As of December 31, 2022, Synlogic had cash, cash equivalents, and short-term marketable securities of $77.6 million. Revenue was $0.1 million for the three ...On November 7, 2023, Synlogic, an innovative biotechnology company, proudly announced that it has reached a significant milestone in its collaboration with Roche. This achievement marks the successful completion of the third pre-specified research milestone, resulting in a milestone payment of $2.5 million. The collaboration between Synlogic ...

Presentations included full data from both the Phase 2 Synpheny-1 Study in phenylketonuria and Phase 1 Study for SYNB1353 as a potential treatment for homocystinuriaCAMBRIDGE, Mass., March 20 ...Upcoming Industry and Banking Conferences. Synlogic will participate in the banking and industry conferences listed below in early 2022. Recorded presentations will be available at https://investor.synlogictx.com.. H.C. Wainwright BIOCONNECT Virtual Conference. Synlogic will present a corporate update at the H.C. Wainwright …Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.

CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ...Synlogic, Inc. CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S ...

١٠‏/٠٦‏/٢٠٢١ ... ... Synlogic's stock price peaked above $50/share. In mid-May, however, the price was just a tenth of that, closing on May 24 at less than $4/share.Founded in 2014 by MIT professors Jim Collins and Tim Lu, Synlogic combines synthetic biology, a form of precision biological engineering, with principles of traditional drug development to design medicines for diseases that are in need of new approaches. The result is a robust engine that can create these potential medicines, called Synthetic ...Sep-22-21 11:32PM. Synlogic Announces Pricing of Public Offering of Common Stock. (PR Newswire) Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory …Synlogic, Inc. (SYBX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 1.8600 -0.0300 (-1.59%) At close: 04:00PM EDT 1.8400 -0.02 (-1.08%) After …SYBX Stock Performance Soars with 1,939.98% Increase: Analysts Predict Strong Growth for Synlogic Inc. SYBX stock had a significant performance on September 27, 2023. The 12-month price forecasts from three analysts for Synlogic Inc had a median target of $5.00, with a high estimate of $6.00 and a low estimate of $4.00.

Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.

Synlogic trades on the NASDAQ stock market under the symbol SYBX. What is Synlogic stock price doing today? As of November 24, 2023, SYBX stock price declined to $2.00 with 12,590 million shares trading.

Synlogic is a biotechnology company that designs Synthetic Biotics, living probiotics that treat diseases with Synthetic Biotic pipeline. The web page provides stock quote, chart, news releases, events, and corporate documents of Synlogic, as well as investor resources and contact information.May 11, 2023 · CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ... ٣١‏/٠١‏/٢٠١٨ ... Was this some sort of “pivot”? Turns out that it's actually a secondary offering, not an IPO, and it is now an entirely new company as a result ...Figure 5: Synlogic Stock Chart (source: finviz) Thus, Synlogic looks like a good value at current levels, although, obviously, still a high-risk investment due to the early stages of its assets.May 4, 2023 · Synlogic, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ... Complete Synlogic Inc. stock information by Barron's. View real-time SYBX stock price and news, along with industry-best analysis.Dec 1, 2023 · Based on short-term price targets offered by three analysts, the average price target for Synlogic, Inc. comes to $21.67. The forecasts range from a low of $6.00 to a high of $35.00. The average ...

SYBX shares carry an average target price of $7.17 yet trade for $0.65. They are therefore a 10X opportunity based on Wall Street consensus. The company reported a small amount of revenue in the ...Synlogic (SYBX) Presents At Jefferies 2017 London Healthcare Conference - Slideshow. SA Transcripts Fri, Nov. 17, 2017 1 Comment. All earnings call transcripts on Synlogic, Inc. (SYBX) stock. Read ...Find the latest Synlogic, Inc. (SYBX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. Common stock and common stock equivalents Common stock 66,736,251 69,698,844 Common stock warrants (pre-funded) 2,548,117 2,548,117 Total common …Synlogic another drug, SYNB1353, had received RPDD in December 2022 to treat homocystinuria (HCU), according to the company. SYBX +12.95% to $1.12 premarket Jan. 19 Recommended For YouStock Quote & Chart Analyst Coverage. Corporate Governance. Governance Highlights Leadership Board of Directors Committee Composition Board Diversity Matrix. ... Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3. October 18, 2022.

Nov 9, 2023 · Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October ... A high-level overview of Synlogic, Inc. (SYBX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Complete Synlogic Inc. stock information by Barron's. View real-time SYBX stock price and news, along with industry-best analysis. Presentations included full data from both the Phase 2 Synpheny-1 Study in phenylketonuria and Phase 1 Study for SYNB1353 as a potential treatment for homocystinuriaCAMBRIDGE, Mass., March 20 ...Information on stock, financials, earnings, subsidiaries, investors, and executives for Synlogic. Use the PitchBook Platform to explore the full profile.Stock Quote & Chart Analyst Coverage. Corporate Governance. Governance Highlights Leadership Board of Directors Committee Composition Board Diversity Matrix. ... Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting. March 20, 2023.Find the latest Synlogic, Inc. (SYBX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. Top Public Companies. #5. Codexis. Revenue: $69.056 million in 2020; $18.032 million in Q1 2021. Codexis on June 17 raised its 2021 investor guidance after receiving a binding purchase order from ...٠١‏/٠٦‏/٢٠٢٠ ... Before use, frozen stocks were evaluated for viability (>90%), purity and functionality as described above. Bacterial strain construction. List ...

On average, Wall Street analysts predict. that Synlogic's share price could reach $82.50 by Aug 11, 2024. The average Synlogic stock price prediction forecasts a potential upside of 4,025% from the current SYBX share price of $2.00.

Nov 30, 2023 · Grading Synlogic Inc Stock. Before you choose to buy, sell or hold Synlogic Inc stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement.

See Synlogic, Inc. (SYBX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Synlogic, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...Complete Synlogic Inc. stock information by Barron's. View real-time SYBX stock price and news, along with industry-best analysis. We are driven by the promise of synthetic biology and by the new possibilities for better health that we believe we can bring to patients. Synlogic is the leading company advancing therapeutics based on synthetic biology, working at the intersection of biology and engineering to treat disease. View the latest Synlogic Inc. (SYBX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Synlogic trades on the NASDAQ stock market under the symbol SYBX. What is Synlogic stock price doing today? As of November 24, 2023, SYBX stock price declined to $2.00 with 12,590 million shares trading.Ginkgo has purchased 6,340,771 shares of Synlogic common stock as well as pre-funded warrants to purchase up to 2,548,117 shares of Synlogic common stock, both at a price of $9.00 per share. Gross proceeds to Synlogic are approximately $80 million. The transactions were executed and closed on June 11, 2019.Synlogic enacted this reverse stock split to boost the price of its shares and avoid delisting. The company’s stock previously closed out trading at just 28 cents. That’s below the $1 minimum ...A high-level overview of Synlogic, Inc. (SYBX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.

With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Share. Share. Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering. Stock Information for Synlogic Inc. Loading. Please wait while we ...CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that SYNB8802 has achieved proof of mechanism in a Dietary Hyperoxaluria study in which healthy volunteers on a high oxalate and low calcium diet were treated with multiple ascending doses of SYNB8802.Instagram:https://instagram. waddell and reeddjia pe ratioadp report todayyy. Institutional investors have sold a total of 13,539,674 shares in the last 24 months. This volume of shares sold represents approximately $97.33M in transactions. Iterum Therapeutics Institutional Ownership. This page (NASDAQ:SYBX) was last updated on 11/16/2023 by MarketBeat.com Staff. penn stoxkshould i buy stocks on cash app Stock Quote & Chart Analyst Coverage. Corporate Governance. Governance Highlights Leadership Board of Directors Committee Composition Board Diversity Matrix. ... Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study. December … best day trading site Synlogic, Inc. (SYBX) is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases. The stock price, news, quote and history of SYBX are available on Yahoo Finance. See the latest performance outlook, earnings date, dividend yield and more. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash ...Synlogic, Inc. (NASDAQ:SYBX) climbed 9.7% to $0.55 in pre-market trading. Synlogic announced the FDA granted orphan drug designation to SYNB1934 for the treatment of phenylketonuria. Losers